Cargando…
Glycoengineered Monoclonal Antibodies with Homogeneous Glycan (M3, G0, G2, and A2) Using a Chemoenzymatic Approach Have Different Affinities for FcγRIIIa and Variable Antibody-Dependent Cellular Cytotoxicity Activities
Many therapeutic antibodies have been developed, and IgG antibodies have been extensively generated in various cell expression systems. IgG antibodies contain N-glycans at the constant region of the heavy chain (Fc domain), and their N-glycosylation patterns differ during various processes or among...
Autores principales: | Kurogochi, Masaki, Mori, Masako, Osumi, Kenji, Tojino, Mami, Sugawara, Shu-ichi, Takashima, Shou, Hirose, Yuriko, Tsukimura, Wataru, Mizuno, Mamoru, Amano, Junko, Matsuda, Akio, Tomita, Masahiro, Takayanagi, Atsushi, Shoda, Shin-Ichiro, Shirai, Takashi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4511734/ https://www.ncbi.nlm.nih.gov/pubmed/26200113 http://dx.doi.org/10.1371/journal.pone.0132848 |
Ejemplares similares
-
Labeling glycans on living cells by a chemoenzymatic glycoengineering approach
por: Almaraz, Ruben T., et al.
Publicado: (2017) -
Chromatographic
Analysis of the N-Glycan Profile on Therapeutic
Antibodies Using FcγRIIIa
Affinity Column Chromatography
por: Hiranyakorn, Methanee, et al.
Publicado: (2023) -
Evaluation of Two Chemoenzymatic Glycan Remodeling Approaches to Generate Site-Specific Antibody–Drug Conjugates
por: Yang, Qiang, et al.
Publicado: (2023) -
Glycoengineering HIV-1 Env creates ‘supercharged’ and ‘hybrid’ glycans to increase neutralizing antibody potency, breadth and saturation
por: Crooks, Ema T., et al.
Publicado: (2018) -
Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development
por: Li, Wei, et al.
Publicado: (2017)